Rx-360 Summary of FDA Draft Guidance for Industry, Development and Submission of Near Infrared Analytical Procedures
Rx-360 has produced a summary of FDA's draft guidance for industry, Development and Submission of Near Infrared Analytical Procedures.
Near infrared (NIR) analytical procedures are increasingly being used in the pharmaceutical industry for the identification and assay of pharmaceutical starting materials, intermediates and finished products. They are also used to monitor and control manufacturing processes. The development and validation of NIR analytical procedures are therefore important for ensuring the quality of pharmaceuticals. It is important for manufacturers who use such procedures to understand the factors that can affect the performance and suitability of the procedures and the approaches that can be used to validate them.
This guidance provides recommendations to applicants of new drug applications (NDAs), abbreviated new drug applications (ANDAs) and drug master file (DMF) holders regarding the development and submission of NIR analytical procedures used during the manufacture and analysis of pharmaceuticals (including raw materials, in-process materials and intermediates, and finished products). It also provides recommendations regarding how the concepts described in the International Conference on Harmonization (ICH) guidance for industry Q2(R1) Validation of Analytical Procedures: Text and Methodology (ICH Q2(R1)) and PAT — A Framework for Innovative Pharmaceutical Development, Manufacturing, and Quality Assurance can be applied to the development, validation, and submission of NIR analytical procedures.
This guidance only pertains to the development and validation of NIR analytical procedures and does not provide recommendations concerning the set-up and qualification of NIR instruments or their maintenance and calibration. Although this guidance is written specifically for NIR, the fundamental concepts of validation can be applied to other PAT technologies including Raman, focused beam reflection measurement, particle imaging, X-ray, among other techniques.
Comments on the draft guidance are due by 1 June 2015.
Related News
-
News Pharmaceutical industry supports COP28 health stance in joint statement
As COP28 takes place over this week in Dubai, UAE, several bodies in the pharmaceutical and health industries have come together to announce support of key movements in sustainability in the sector, and to recognise sustainability as a health issue.&nb... -
News Biden backs Cold-War measures to shore-up medical supply chains
In a recent strategy to combat rising inflation and the cost of living crisis, President Joe Biden has invoked a Cold War-era act to increase investment in a selection of medicines and supplies. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Novartis agrees for copies to be made of cancer drug to reach poorer countries
Novartis signs agreement with MPP to have generics of it's leukemia drug made so that it can be more easily distributed to the world's poorer countries. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute. -
News New WHO health emergency guidelines expect full transparency from Big Pharma
The WHO are proposing a new set of pandemic guidelines to set out how future global health crises should be handled.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance